Arthneeti
All Q2 FY26 results →
AP

AstraZeneca PLC

Q2 FY26Pharmaceuticals

AstraZeneca PLC Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹185
Market cap₹5.7L Cr
P/E28.1
Updated29 May 2026
Read4 min read

What the Q2 FY26 call signalled

1 of 3 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned

The short version

- Total revenue growth: AstraZeneca expects mid- to high single-digit percentage increase for the full year 2026. - Oncology: 16% revenue growth in Q1 2026; continued growth expected with strong momentum in key products like Tagrisso, Imfinzi, Calquence, HER2 portfolio, and Datroway. - Biopharmaceuticals: Stable total revenue with growth in respiratory and immunology portfolio (+7%), driven by brands like Fasenra (+11%) and Breztri (+13%). - Pipeline & launches: Significant growth anticipated from upcoming launches such as baxrostat, gamizestrant, tozorakimab, and amplifying commercial investments. - Tozorakimab: Potential to be a $3-$5 billion asset with upside toward $10 billion depending on additional indications. - Tagrisso: Mid-teens demand growth expected, with stable U.S. - AstraZeneca expects total revenue to increase by mid- to high single-digit percentage in 2026.

From AstraZeneca PLC's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Moderate growth
  • Total revenue growth: AstraZeneca expects mid- to high single-digit percentage increase for the full year 2026.
  • Oncology: 16% revenue growth in Q1 2026; continued growth expected with strong momentum in key products like Tagrisso, Imfinzi, Calquence, HER2 portfolio, and Datroway.
  • Biopharmaceuticals: Stable total revenue with growth in respiratory and immunology portfolio (+7%), driven by brands like Fasenra (+11%) and Breztri (+13%).
  • Pipeline & launches: Significant growth anticipated from upcoming launches such as baxrostat, gamizestrant, tozorakimab, and amplifying commercial investments.
  • Tozorakimab: Potential to be a $3-$5 billion asset with upside toward $10 billion depending on additional indications.

2 more points from AstraZeneca PLC's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what AstraZeneca PLC said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • CapEx for Q1 2026 was $600 million, including previously announced multiyear investments.
  • Key investments include a new ADC (antibody-drug conjugate) manufacturing facility in Singapore.
  • Construction of a new manufacturing plant in Qingdao, China, focused on inhaled respiratory portfolio.
  • CapEx is anticipated to increase by around one-third in 2026.
  • Strategic investments continue in transformative technologies such as cell therapies and T-cell engagers to drive growth beyond 2030.
  • Milestone payments of around $2.5 billion are expected for the full year, related to past transactions.

2 more points from AstraZeneca PLC's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what AstraZeneca PLC said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant insights related to product demand and market performance include: - Tagrisso shows strong underlying demand growth in the US with mid-teens percentage growth, despite some wholesale destocking impacting net results. - Ongoing Phase III studies and broader program openings are expected to drive further demand and market expansion (e.g., for compound 120 in multiple myeloma). - Biopharmaceuticals portfolio is broadly stable with growth in key brands offsetting headwinds; respiratory and immunology portfolio up 7% to $2.3 billion.

2 more points from AstraZeneca PLC's call on order book

Create a free account to keep reading this call

Continue your research

Others in Pharmaceuticals this season

  • Elanco Animal Health Incorporated (Q2 FY26)

    Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S

  • Axsome Therapeutics, Inc. (Q2 FY26)

    Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from

  • Jazz Pharmaceuticals plc (Q2 FY26)

    Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo

  • Viatris Inc. (Q2 FY26)

    Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7

Compare:vs Johnson & Johnsonvs Novartis AGvs Novo Nordisk A/S

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

AstraZeneca PLC and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were AstraZeneca PLC Q2 FY26 results?

- Total revenue growth: AstraZeneca expects mid- to high single-digit percentage increase for the full year 2026. - Oncology: 16% revenue growth in Q1 2026; continued growth expected with strong momentum in key products like Tagrisso, Imfinzi, Calquence, HER2 portfolio, and Datroway. - Biopharmaceuticals: Stable total revenue with growth in respiratory and immunology portfolio (+7%), driven by brands like Fasenra (+11%) and Breztri (+13%). - Pipeline & launches: Significant growth anticipated from upcoming launches such as baxrostat, gamizestrant, tozorakimab, and amplifying commercial investments. - Tozorakimab: Potential to be a $3-$5 billion asset with upside toward $10 billion depending on additional indications. - Tagrisso: Mid-teens demand growth expected, with stable U.S. - AstraZeneca expects total revenue to increase by mid- to high single-digit percentage in 2026.

What is AstraZeneca PLC share price analysis?

AstraZeneca PLC currently shows a below-average growth signal. The stock trades at a P/E of 28.1 with a market cap of $574,792. Investors should review the full earnings analysis for detailed insights.

Is AstraZeneca PLC planning capital expenditure?

- CapEx for Q1 2026 was $600 million, including previously announced multiyear investments.

Keep AstraZeneca PLC on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.